Sonia Basantani’s Post

Biotech companies developing therapies for rare and orphan diseases often face challenges in bringing their innovative treatments to market. Expanded access programs (EAPs) can be a crucial step in making these life-saving drugs available to patients who have exhausted all other options, even before full regulatory approval. Based on over 30 years of expertise in handling rare and ultra-rare disease medications, we've shared our insight for US and EU biotechs on the key considerations, steps, and strategies needed to establish a successful EAP in Europe. Read more here: https://lnkd.in/eHCMYhYw #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldData #Biotechs #PatientAccess #MarketAccess

Today (on the rarest day of the year), we stand in solidarity with millions worldwide to commemorate Rare Disease Day. Each story is unique, each journey marked by resilience, courage, and unwavering determination. There are more than 6,000 different rare diseases, affecting some 36 million people just in the EU (300 million individuals worldwide). Most people suffer from diseases that affect less than 1 in 100,000 people 🎯 At Mabion S.A., we believe that there is a huge demand for advanced therapies in indications that, due to smaller patient populations, do not receive the attention of major players in the pharmaceutical market. We're committed to making a difference in the lives of those affected by rare diseases 🤝 Through #innovation, #collaboration and tireless dedication, we strive to develop treatments that offer hope and healing to those who need it most. In our view, oprhan drugs is a very important, under-addressed segment of the pharmaceutical market, while also being very attractive to dynamic companies that are technologically and organizationally advanced. ❗Together, we can make a difference❗#RareDiseaseDay

Continuing with the review of medical waste, Novo Nordisk has established a circular system for the disposal of insulin pens they manufacture and sell. (1) Novo Nordisk utilises reverse logistics as part of its collection system. (2) There is also a mail-back option (offering consumer choice) (3) They utilise as much of the materials as possible. (4) Works at scale (why removing the sharp is critical to reprocessing company) **Novo Nordisk does not disclose how much residual materials (waste) are left after making chairs and glass products. The International Diabetes Federation (IDF) estimates that over 537 million people all over the world are currently struggling with diabetes mellitus (DM). There are about 150–200 million of them treated with insulin. The usage of insulin pens: in the US rose to 59% whereas in Europe it is comparably high and assessed to be 93.6%. According to the International Diabetes Federation: It is predicted that diabetes will rise to 643 million by 2030 and 783 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Karen Laird - Don Loepp

𝗘𝘆𝗹𝗲𝗮 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗶𝘇𝗲 𝗔𝗻𝗱 𝗙𝗼𝗿𝗲𝗰𝗮𝘀𝘁 Eylea Market size was valued at USD 8.80 Billion in 2023 and is projected to reach USD 14.31 Billion by 2030, growing at a CAGR of 7.3% during the forecasted period 2024 to 2030. 𝗞𝗲𝘆 𝗗𝗿𝗶𝘃𝗲𝗿𝘀: ※ Ageing Population: As age-related macular degeneration grows increasingly common with age, the ageing population globally is a major driver of the Eylea market. ※ Growing Incidence of Eye illnesses: A number of factors, including alterations in lifestyle, a rise in the frequency of diabetes, and extended screen time, have led to an increase in the incidence of eye illnesses worldwide, which has raised demand for drugs like Eylea. ※ Technological Developments: Improvements in drug delivery methods and diagnostic tools have made it easier to identify and treat eye conditions, which has increased demand for drugs like Eylea. ※ Growing Healthcare Expenditure: As a result of increased global healthcare spending, cutting-edge medicines like Eylea are now more accessible and affordable, which is fueling market expansion. 𝗞𝗲𝘆 𝗣𝗹𝗮𝘆𝗲𝗿𝘀: Regeneron Bayer Santen Pharmaceutical Momenta Pharmaceuticals Novartis Mylan 𝗚𝗲𝘁 𝗠𝗼𝗿𝗲 𝗗𝗲𝘁𝗮𝗶𝗹𝘀: https://bit.ly/3WzVAmQ #Eylea #Market #forecast

Thoughts on this? >> Early Roche Alzheimer’s data ‘worth watching’ as long-term Leqembi, donanemab competitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharma #pharmaceutical #healthcare

Novo Nordisk (NVO 0.28%) is a leading brand in the healthcare industry. Its diabetic treatment, Ozempic, is now a well-known and hot social media issue. Individuals taking the medication to aid with weight loss are seeing amazing results. Because of its unusual nature, companies in other sectors of the economy, including the food industry, are also being asked to respond to questions about the potential effects Ozempic could have on their business activities and future growth. This makes sense as to why investors like Novo Nordisk stock so much. Its shares have risen more than 40% only this year. If you had bought the shares five years earlier before Ozempic changed the game for the company, how much would you have gained? Read our full blog here: https://lnkd.in/eyuWiUVr #panterrafinance #novonordisk #ozempic #blog

Thoughts on this? >> Novo Nordisk looks beyond weight loss and diabetes to expand in new illnesses >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #productmarketing #biotech

Thoughts on this? >> Novo Nordisk looks beyond weight loss and diabetes to expand in new illnesses >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #pharma #productmarketing #healthcare

Honeywell announced a long-term supply agreement with DevPro Biopharma to develop a new respiratory inhaler aimed at enhancing patient well-being while significantly reducing carbon emissions. Utilizing Honeywell's Solstice® Air HFO-1234ze technology, this albuterol inhaler will achieve a 99.9% reduction in carbon emissions compared to traditional inhalers without compromising efficacy. This agreement addresses the pressing need for environmentally friendly inhalers for the 384 million people globally suffering from Chronic Obstructive Pulmonary Disease (COPD) and 262 million with asthma. Clinical trials for the new inhaler are expected to start in 2025, with consumer availability projected for early 2027. Read more about the agreement here:

As the results below rolled in this morning, I turned the page to start my 5. year in this lovely company. 4 years ago I closed my management consultancy, said good bye to exec salary and 10 weeks holiday. I returned to where I was an intern. That career U-turn created a lot of questions: A. How could you leave your own company? You can be a lifestyle entrepreneur or pure business. I was the last - it was just a job. B. Why move into corporate? I grew up in Accenture - so very corporate. It's just nice when things are professional, successful and international. C. Is it boring to be in the same org? At Novo Nordisk never a dull moment, since we grow like a startup. International consulting is addicting because you see so much, hence learn so much (that's why I stayed 20+ years) - but it's also kind of nice for your wellbeing that every day is not an exam to justify a 3k eur fee. Nice to have good colleagues long term, not to travel like crazy and a pleasure to be a tiny part of this historic journey. So all good from Bagsværd 😁 It has been a super move 👍 Thx.